Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Phase Forward: Boooooring
- Phase Forward monitors clinical trials around the world and spurred the move to web-based trials ten years ago. But their boring technology helps us all not die from the latest meds. Which is sort of exciting.
- Videos 2008-04-02
Additional Resources
- Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: From clinical trails to clinical practice
- Radioimmunotherapy RIT is a new treatment modality for B-- cell non-Hodgkin's lymphoma NHL. Recent clinical trials have clearly established its efficacy in NHL patients refractory to standard chemotherapy or immunotherapy with the widely used unconjugRadioimmunotherapy RIT is a new treatment modality for B-- cell non-Hodgkin's lymphoma NHL. Recent clinical trials...
- Research articles 2002-11-01
- NeoRx and ABC Labs Extend Clinical Manufacturing Agreement
- Business Editors, Health/Medical Writers SEATTLE--BUSINESS WIRE--Jan. 30, 2001 NeoRx Corporation (Nasdaq:NERX) and ABC Laboratories (Columbia, MO) have extended their existing agreement for ABC Laboratories to manufacture NeoRx's STR product for the Phase III clinical trials in multiple myeloma. ABC Laboratories had supplied doses of STR for the Phase...
- Research articles 2001-01-30
- Genentech and Alkermes Announce Plans to Advance ProLease Human Growth Hormone to Phase III Clinical Trials
- SOUTH SAN FRANCISCO, Calif.--BW HealthWire--Nov. 24, 1997-- Based on results of a U.S. Phase II trial of ProLeaseR human growth hormone hGH, Genentech, Inc. (NYSE:GNE) and Alkermes, Inc. (NASDAQ:ALKS) announced today that they will advance clinical studies of this potential therapy to pivotal Phase III clinical trails in growth hormone...
- Research articles 1997-11-24
- Reforming clinical trials.(Regulatory Update)(Brief Article)
- The American Medical Association AMA has recently called for the Dept. of Health and Human Services to create a comprehensive registry for all clinical trails conducted in the U.S. The move is part of a growing effort to address concerns over the pharmaceutical industry's impact on...
- Research articles 2004-07-01
- Avitar announces successful completion of clinical trials of drugs of abuse tests for amphetamine and methamphetamine by its associate, Sun Biomedical Laboratories
- CANTON, Mass.--BUSINESS WIRE--March 6, 1997--Avitar, Inc. ("the Company") [Nasdaq SmallCap Market:AVIT Common Stock; AVITW Redeemable Warrants] today announced the successful completion of clinical trails of the Visualine II urine drugs of abuse tests for amphetamine and methamphetamine. These rapid point of care tests were compared to licensed laboratory tests...
- Research articles 1997-03-06
- Sinovac Biotech Limited Q2 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions. Thank you. Our first question today is coming from [Dan Jaffrey], a Private Investor. Please state your question, sir. Dan Jaffrey – Private Investor Yes. I have a few questions, one is do you have any kind of even rough timetable about what...
- Earnings calls 2009-08-19
- MediSolution signs contracts totalling $1.3 million with Boundary Trails Health Centre.
- MONTREAL, Oct 04, 2000 MediSolution Ltd. (MSH:TSE) has signed two contracts valued at more than $1.3 million to provide an electronic patient record and to deliver and integrate a picture archiving communications system PACS into the information management systems of the Boundary Trails Health...
- Research articles 2000-10-04
- Therapeutic Monoclonal Antibodies Manufacturers Focus on Eliminating Clinical Trial Complexities to Sustain Growth
- PALO ALTO, Calif. -- Manufacturers in the U.S. therapeutic monoclonal antibodies mAb market face their biggest challenge in the form of huge costs and complexities in clinical trials. A typical trial takes 10 to 15 years with a cost range of $800 million to 1 billion for developing a product....
- Research articles 2005-06-27
- AstraZeneca's, Bristol-Myers' Phase II drugs
- AstraZeneca and Bristol-Myers Squibb lead the industry in new advanced-stage cardiovascular drugs in clinical trails with three each in Phase III. In all, there are 122 new medicines currently in development to treat heart disease and stroke, according to a survey released by PhRMA.
- Research articles 2001-03-01
- BIOGEN Inc. and Elan corporation PLC.(Companies to cooperate to develop monoclonal antibodies for treatment of MS and Crohn's disease)(Brief Article)
- BIOGEN Inc. and Elan corporation PLC have formed an agreement to develop, manufacture and commercialize Antegren natalizumab, a ... BIOGEN Inc. and Elan corporation PLC have formed an agreement to develop, manufacture and commercialize Antegren natalizumab, a humanized monoclonal antibody nearing completion of Phase...
- Research articles 2000-08-28
- Drug rush isn't easy to explain: Novogen.
- Dec 4, 2001 The Australian ABIX via COMTEX -- The reason the Novogen share price has increased two-fold in the 14 days to 3 December 2001 is obscure. The Australian biotechnology company's two major drugs, phenoxodial and promensil, remain in the early stages of...
- Research articles 2001-12-03
- SCOLR Pharma Announces Positive Ibuprofen Study Results and Status of Commercialization Program
- Positive Results from Two Pharmacokinetic Trails Completed on 64 Subjects; Plans to Submit a U.S. New Drug Application in Latter Half of 2008; Reacquires Technology for Global Rights for Ibuprofen Products BELLEVUE, Wash. -- SCOLR Pharma, Inc. (AMEX: DDD) announced today two additional positive pharmacokinetics ("PK") trials evaluating its...
- Research articles 2007-04-17
- Peregrine Pharmaceuticals, Inc. F4Q09 (Qtr End 04/30/09) Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions Your first question comes from Stephen Dunn – Jesup & Lamont. Stephen Dunn – Jesup & Lamont Can you give us a little color or guidance of when we would expect to see data from the multitude of phase II trials? ...
- Earnings calls 2009-07-14
- Javelin Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions. We’ll take our first question from Gary Nachman - Leerink Swann. Gary Nachman - Leerink Swann First question on the Ereska data; Marty, what did you mean that the outcome could change in the future after you examine all aspects of the data,...
- Earnings calls 2009-08-11
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
